The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus
Faron Pharmaceuticals Ltd. announced a fully committed rights offering of approximately EUR 40 million, which has received approval from the Finnish Financial Supervisory Authority. The offering will involve up to 80,000,000 new shares and 158,126 treasury shares, with subscription periods commencing on March 17, 2026, for shares and depository interests. Subscription rights will be transferable and tradeable on Nasdaq First North Growth Market Finland and AIM until March 27, 2026. The company will host an offering webcast on March 17, 2026, to discuss development plans and the rationale for the offering.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | March 11, 2026 at 20:20:00 EET |
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON, “Faron” or the “Company”) announced through a company announcement on 10 March 2026 a resolution by the Company’s Board of Directors on a fully committed rights offering of approximately EUR 40 million (the “Offering”) as well as the terms and conditions of the Offering. In the Offering, the Company will offer for subscription, based on pre-emptive rights for existing shareholders, a maximum of 80,000,000 new shares in the Company under the authorisation granted by the Extraordinary General Meeting of the Company held on 2 March 2026 and a maximum of 158,126 treasury shares in the Company under the authorisation granted by the Annual General Meeting of the Company held on 21 March 2025 (the “Offer Shares”) which may be represented by depository interests (“DIs”) (“Offer DIs”).
The Finnish Financial Supervisory Authority has today on 11 March 2026 approved the Finnish language prospectus (the “Finnish Prospectus”) prepared in relation to the Offering.
The Finnish Prospectus and the document incorporated therein by reference (together, the “Offering Documents”), will be available on or about 11 March 2026 at the website of the Company at www.faron.fi/merkintaoikeusanti-2026.
The English language offering circular and the document incorporated therein by reference will be available on or about 11 March 2026 on the website of the Company at https://faron.com/rights-offering-2026/.
The subscription period for the Offer Shares will commence on 17 March 2026 at 10.00 a.m. (Finnish time) and expire on 2 April 2026 at 4.30 p.m. (Finnish time). The subscription period for the Offer DIs will commence on 17 March 2026 at 8.00 a.m. (London time) and expire on 31 March 2026 at 11:00a.m. (London time). The subscription rights are freely transferable, and they are subject to trading on Nasdaq First North Growth Market Finland maintained by Nasdaq Helsinki Ltd under the trading code “FARONU0126” (ISIN code: FI4000602313) between 17 March 2026 and 27 March 2026, and in the form of DIs on AIM under the trading code “FARONU0126” (ISIN code: FI4000602313), the market of that name operated by London Stock Exchange plc between 17 March 2026 and 27 March 2026.
Stifel Europe Securities SAS acts as the sole global coordinator and bookrunner in respect of the Offering (the “Sole Global Coordinator and Bookrunner”). Roschier, Attorneys Ltd. acts as the Company’s legal adviser in Finland and Freshfields LLP acts as the Company’s legal adviser as to U.S. federal securities law and U.K law. Krogerus Attorneys Ltd. acts as the Sole Global Coordinator and Bookrunner’s legal adviser in Finland and Milbank LLP acts as the Sole Global Coordinator and Bookrunner’s legal adviser in the United Kingdom and the United States. IR Partners Oy acts as the Company’s communications adviser.
Offering webcast
The Company will host a virtual offering webcast on Tuesday, 17 March 2026. The offering webcast will be held in Finnish and English. The Finnish-language webcast starts at 5 p.m. EET, and the English-language webcast starts at 6 p.m. EET. During the event, Faron’s Chief Executive Officer, Dr. Juho Jalkanen and other members of Faron’s management team will provide an update on the Company’s development plans and the rationale behind the Offering.
Finnish-language offering webcast registration link
English-language offering webcast registration link
About bexmarilimab
Caution regarding forward-looking statements
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.